X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AJANTA PHARMA with Lupin Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs LUPIN LTD - Comparison Results

LUPIN LTD 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA LUPIN LTD AJANTA PHARMA/
LUPIN LTD
 
P/E (TTM) x 19.9 29.2 68.0% View Chart
P/BV x 4.6 2.8 164.8% View Chart
Dividend Yield % 0.0 0.6 -  

Financials

 AJANTA PHARMA   LUPIN LTD
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-18
LUPIN LTD
Mar-18
AJANTA PHARMA/
LUPIN LTD
5-Yr Chart
Click to enlarge
High Rs1,8181,465 124.1%   
Low Rs1,106727 152.1%   
Sales per share (Unadj.) Rs239.5349.6 68.5%  
Earnings per share (Unadj.) Rs52.85.6 949.9%  
Cash flow per share (Unadj.) Rs59.529.6 201.2%  
Dividends per share (Unadj.) Rs05.00 0.0%  
Dividend yield (eoy) %00.5 0.0%  
Book value per share (Unadj.) Rs230.0300.3 76.6%  
Shares outstanding (eoy) m88.77452.08 19.6%   
Bonus/Rights/Conversions -ESOPS-  
Price / Sales ratio x6.13.1 194.7%   
Avg P/E ratio x27.7197.2 14.0%  
P/CF ratio (eoy) x24.637.1 66.3%  
Price / Book Value ratio x6.43.6 174.2%  
Dividend payout %090.0 0.0%   
Avg Mkt Cap Rs m129,782495,502 26.2%   
No. of employees `0006.817.0 39.9%   
Total wages/salary Rs m3,76528,647 13.1%   
Avg. sales/employee Rs Th3,128.49,273.6 33.7%   
Avg. wages/employee Rs Th554.01,681.0 33.0%   
Avg. net profit/employee Rs Th689.7147.4 467.8%   
INCOME DATA
Net Sales Rs m21,258158,042 13.5%  
Other income Rs m2421,504 16.1%   
Total revenues Rs m21,499159,545 13.5%   
Gross profit Rs m6,58431,475 20.9%  
Depreciation Rs m59610,859 5.5%   
Interest Rs m42,044 0.2%   
Profit before tax Rs m6,22620,076 31.0%   
Minority Interest Rs m0-71 0.0%   
Prior Period Items Rs m035 0.0%   
Extraordinary Inc (Exp) Rs m0-14,644 0.0%   
Tax Rs m1,5392,885 53.4%   
Profit after tax Rs m4,6862,513 186.5%  
Gross profit margin %31.019.9 155.5%  
Effective tax rate %24.714.4 172.1%   
Net profit margin %22.01.6 1,386.7%  
BALANCE SHEET DATA
Current assets Rs m12,236122,095 10.0%   
Current liabilities Rs m3,46150,956 6.8%   
Net working cap to sales %41.345.0 91.7%  
Current ratio x3.52.4 147.6%  
Inventory Days Days6085 71.2%  
Debtors Days Days84120 70.5%  
Net fixed assets Rs m11,140129,876 8.6%   
Share capital Rs m177904 19.6%   
"Free" reserves Rs m20,237134,866 15.0%   
Net worth Rs m20,414135,771 15.0%   
Long term debt Rs m1064,245 0.0%   
Total assets Rs m24,486263,054 9.3%  
Interest coverage x1,519.410.8 14,036.8%   
Debt to equity ratio x00.5 0.1%  
Sales to assets ratio x0.90.6 144.5%   
Return on assets %19.21.7 1,106.0%  
Return on equity %23.01.9 1,240.5%  
Return on capital %30.53.7 819.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m11,66753,141 22.0%   
Fx outflow Rs m1,61619,335 8.4%   
Net fx Rs m10,05233,807 29.7%   
CASH FLOW
From Operations Rs m2,85417,512 16.3%  
From Investments Rs m-2,604-14,073 18.5%  
From Financial Activity Rs m-2-14,921 0.0%  
Net Cashflow Rs m248-11,482 -2.2%  

Share Holding

Indian Promoters % 73.8 46.6 158.4%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 1.6 11.3 13.7%  
FIIs % 7.6 31.9 23.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 10.1 168.3%  
Shareholders   20,968 98,259 21.3%  
Pledged promoter(s) holding % 4.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   ALEMBIC LTD  SUN PHARMA  PIRAMAL ENTERPRISES  FDC LTD.  AUROBINDO PHARMA  

Compare AJANTA PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Of WPI-Inflation Data, Q2FY19 Results, and Top Stocks in Focus Today(Pre-Open)

Share markets in India ended their trading session on a flattish note yesterday. Sectoral indices ended on a mixed note with stocks in the IT sector.

Related Views on News

LUPIN LTD Announces Quarterly Results (2QFY19); Net Profit Down 31.1% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, LUPIN LTD has posted a net profit of Rs 3 bn (down 31.1% YoY). Sales on the other hand came in at Rs 40 bn (up 53.1% YoY). Read on for a complete analysis of LUPIN LTD's quarterly results.

AJANTA PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 4.9% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, AJANTA PHARMA has posted a net profit of Rs 1 bn (down 4.9% YoY). Sales on the other hand came in at Rs 5 bn (up 0.7% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

Insider Buying: These Owner Operators Are Taking Advantage of the Correction(Chart Of The Day)

Nov 2, 2018

We believe insider buying is one of the strongest smart money indicators.

Are Fund Houses Opening Up Their NFO Factories Again?(Outside View)

Nov 2, 2018

PersonalFN sheds light on FY 2018-19 so far, the mutual fund industry has collectively launched 84 New Fund Offers (NFOs), of which some are still open for subscription.

Does it Make Sense to Invest in Offshore Funds?(Outside View)

Nov 6, 2018

Many investors prefer to invest in offshore funds because of the rupee depreciation and on-going downtrend in the markets, but it is to be invested only when there is no option available to invest in India.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Nov 14, 2018 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 8-QTR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS